SCHEMBL5218458

SCHEMBL5218458

CCCCOc1ccc(CNC(=O)Oc2ccc3ncccc3c2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 7/20 0.66
ALDH1A1 P00352 2/20 0.60
PPARG P37231 1/20 0.52
PPARA Q07869 1/20 0.52
ALOX5 P09917 1/20 0.51
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CLK1 P49759 1/20 0.45
CLK2 P49760 1/20 0.45
DYRK1A Q13627 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45
DYRK1B Q9Y463 1/20 0.45
MAPT P10636 2/20 0.45
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
KDM4E B2RXH2 1/20 0.44
MAPK1 P28482 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MCL1 Q07820 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5216430 0.86 FAAH (0.71) FAAHPPARGPPARALMNARAB9A
SCHEMBL13491344 0.85 LMNA (0.63) FAAHPPARGPPARALMNASMN1; SMN2
SCHEMBL2335154 0.83 ALDH1A1 (0.64) ALDH1A1
SCHEMBL2329863 0.83 ALDH1A1 (0.64) ALDH1A1
SCHEMBL13491393 0.83 LMNA (0.60) FAAHLMNASMN1; SMN2MAPTHPGD
SCHEMBL13491495 0.82 LMNA (0.59) FAAHLMNASMN1; SMN2MAPTHPGD
SCHEMBL5250058 0.80 FAAH (0.64) FAAHALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL13491494 0.80 TSHR (0.61) ALDH1A1LMNASMN1; SMN2CLK1CLK2
SCHEMBL5214564 0.80 FAAH (0.66) FAAHALDH1A1PPARGPPARAALOX5
SCHEMBL5219284 0.79 FAAH (0.78) FAAHALDH1A1LMNARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1472215-A4 (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2007-05-09 EP claimed
US-20050131032-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors SIT SING-YUEN (US) 2005-06-16 US claimed
EP-1472215-A2 (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS Bristol-Myers Squibb Company (US) 2004-11-03 EP claimed
US-20030195226-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors SIT SING-YUEN (US) 2003-10-16 US claimed
WO-2003065989-A2 (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-08-14 WO claimed
US-6949574-B2 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2005-09-27 US disclosed
US-20050131032-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors SIT SING-YUEN (US) 2005-06-16 US disclosed
US-20030195226-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors SIT SING-YUEN (US) 2003-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195226-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors FAAH, FAAH2, NCEH1 FAAH 1/4885ALDH1A1 394/4885PPARG 258/4885
US-20050131032-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors FAAH, FAAH2, NCEH1 FAAH 1/4885ALDH1A1 394/4885PPARG 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.